JPMorgan downgraded Rocket Pharmaceuticals (RCKT) to Underweight from Neutral without a price target The firm believes Rocket has an “interesting” gene therapy portfolio primarily aimed at rare, genetically driven heart conditions. While the shares as ascribing minimal pipeline credit, the setup is challenging for upside over the next 12 months, the analyst tells investors in a research note. JPMorgan sees risks with Rocket’s lead program in Danon disease.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCKT:
- Buy Rating for Rocket Pharmaceuticals: Strategic Progress and Strong Financial Position Drive Positive Outlook
- Rocket Pharmaceuticals Reports Q3 2025 Financial Results
- Rocket Pharmaceuticals reports Q3 EPS (45c), consensus (52c)
- RCKT Upcoming Earnings Report: What to Expect?
- Rocket Pharma’s Danon Disease Study: A Strategic Move in Genetic Cardiomyopathy